Neurocrine settles INGREZZA patent litigation; generic entry delayed to 2040

NEUROCRINE BIOSCIENCES INC

Settlement with Sandoz and Crystal grants generic INGREZZA license starting Feb 1, 2040, or earlier under certain conditions.
Patent litigation resolved for one ANDA filer; two other ANDA challenges remain pending with trial set for Jan 2, 2024.
Agreement to be submitted to FTC and DOJ as required by law.
INGREZZA is Neurocrine's drug for tardive dyskinesia and Huntington's chorea.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.